Glatiramer is an artificial
protein that resembles a natural myelin protein. It is
not known exactly how the medicine works. But it may help people who have
multiple sclerosis (MS) by preventing the body's
immune system from attacking the myelin coating that
protects nerve fibers.
Glatiramer is given as an injection
beneath the skin one time a day.
Glatiramer is used
to treat people with MS who have relapses followed by periods of recovery
(relapsing-remitting MS). Findings from clinical trials show that people treated soon after being diagnosed with MS may have better results than those who delay treatment.
The National Multiple Sclerosis Society recommends that people who have a definite diagnosis of MS and active, relapsing disease start treatment with interferon beta or glatiramer. This groups adds that treatment with medicine may also be considered after the first attack in some people who are at a high risk for MS.1
Some people have only one episode of a
neurological symptom such as
optic neuritis. Yet
MRI tests suggest these people have MS. This is known
as a clinically isolated syndrome. Many of these people go on to develop MS
over time. In some cases, doctors will prescribe medicine (either interferon
beta or glatiramer) for people who have had a clinically isolated syndrome.
These medicines, when taken early or even before you have been diagnosed with
MS, may keep the disease from getting worse or may extend your time without
reduces the frequency of
relapses in those who have relapsing-remitting MS. It also
slows the number of new lesions (tissue damage) as seen on MRI and decreases
Glatiramer has not been shown to be
effective for people who have
secondary progressive MS. Also, the medicine is not
helpful for people who have
primary progressive MS.
All medicines have side effects. But many people don't feel the side effects, or they are able to deal with them. Ask your pharmacist about the side effects of each medicine you take. Side effects are also listed in the information that comes with your medicine.
Here are some important things to think about:
or other emergency services right away if you have:
Call your doctor if you have:
Common side effects of this medicine include:
See Drug Reference for a full list of side effects. (Drug
Reference is not available in all systems.)
Follow your doctor's instructions on how to use this medicine. Do not give yourself an injection in the same place as your previous injection. Always change the site of the next injection.
The National Multiple Sclerosis Society recommends that people with a definite diagnosis of MS and active, relapsing disease start treatment with interferon or glatiramer. The group adds that medicine may also be considered after the first attack in some people at high risk for MS but before it is diagnosed.1
In addition to side effects, there are some drawbacks to treatment with
If you are taking glatiramer, do not stop taking it
without first talking with your doctor.
Medicine is one of the many tools your doctor has to treat a health problem. If you don't take your medicines properly, you may be putting your health (and perhaps your life) at risk.
There are many reasons why people have trouble taking their medicine. But in most cases, there is something you can do. For suggestions on how to work around common problems, see the topic Taking Medicines as Prescribed.
If you are pregnant, breast-feeding, or planning to get pregnant, do not use any medicines unless your doctor tells you to. Some medicines can harm your baby. This includes prescription and over-the-counter medicines, vitamins, herbs, and supplements. And make sure that all your doctors know that you are pregnant, breast-feeding, or planning to get pregnant.
Follow-up care is a key part of your treatment and safety. Be sure to make and go to all appointments, and call your doctor if you are having problems. It's also a good idea to know your test results and keep a list of the medicines you take.
Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.
National Clinical Advisory Board of the National Multiple Sclerosis Society (2008). Disease Management Consensus Statement. New York: National Multiple Sclerosis Society. Available online: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/expert-opinion-papers/index.aspx.
Faggiano CM, et al. (2008). Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database of Systematic Reviews (2).
Mikol DD, et al. (2008). Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurology, 7(10): 903–914.
May 14, 2012
Adam Husney, MD - Family Medicine
& Anne C. Poinier, MD - Internal Medicine & Barrie J. Hurwitz, MD - Neurology
How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2013 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
We are happy to take your appointment request over the phone, or, you may fill out an online request form.
Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.